Search research articles
Contact Us
Filters
Showing results (41-50 of 71) with videos related to
Page
of 8
Sort By:
European Journal of Heart Failure
|
June 16, 2020
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF
Pooja Dewan, Scott D Solomon, Pardeep S Jhund, et al.
Annals of Internal Medicine
|
April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial
Jawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology
|
March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial
Jawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation
|
April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
Pardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Circulation
|
November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
Circulation
|
August 16, 2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F Docherty, Paul Welsh, Subodh Verma, et al.
Circulation
|
April 20, 2022
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F Docherty, Hiddo J L Heerspink, et al.
Diabetes Care
|
December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Silvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
European Journal of Heart Failure
|
November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF
Jawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure
|
December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
Kieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 71) with videos related to
Sort By:
Page
of 8
European Journal of Heart Failure
|
June 16, 2020
Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF
Pooja Dewan, Scott D Solomon, Pardeep S Jhund, et al.
Annals of Internal Medicine
|
April 25, 2022
Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial
Jawad H Butt, Pooja Dewan, Béla Merkely, et al.
JAMA Cardiology
|
March 31, 2021
Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial
Jawad H Butt, Kieran F Docherty, Mark C Petrie, et al.
Circulation
|
April 9, 2021
Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
Pardeep S Jhund, Piotr Ponikowski, Kieran F Docherty, et al.
Circulation
|
November 19, 2019
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial
Mikhail N Kosiborod, Pardeep S Jhund, Kieran F Docherty, et al.
Circulation
|
August 16, 2022
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F Docherty, Paul Welsh, Subodh Verma, et al.
Circulation
|
April 20, 2022
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F Docherty, Hiddo J L Heerspink, et al.
Diabetes Care
|
December 23, 2020
Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF
Silvio E Inzucchi, Kieran F Docherty, Lars Køber, et al.
European Journal of Heart Failure
|
November 12, 2021
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF
Jawad H Butt, Kieran F Docherty, Pardeep S Jhund, et al.
JACC. Heart Failure
|
December 31, 2021
Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction
Kieran F Docherty, Modele O Ogunniyi, Inder S Anand, et al.
Page
of 8